Tessera Diagnostics Inc.

Tessera Diagnostics, founded in December 2000, is focusing on developing a group of protein markers for early detection of cancer. It's first indication is prostate cancer, and it has in-licensed a group of 14 markers from a family of proteins called NMPs for early detection of the disease. It believes some of these markers are specific and highly sensitive to the disease, and as a group they will provide better information than any test currently available.